Search

Displaying results 6781 - 6790 of 8170 in total
  1. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic

  2. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  3. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814] Its distinguishing feature is its tetrameric structure carrying four chelated gadolinium ions with high relaxivity, which allows an adequately enhanced examination to be obtained while delivering

  5. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  7. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  8. Drug

    AGS-16C3F

    go.drugbank.com/drugs/DB17551
    Investigational

    AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate.

  9. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.

  10. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping...